Lexaria Bioscience Corp. reported results for the 2026 quarter with revenue of $0 and a diluted loss per share of ($0.08); net loss narrowed to ($1.99M) from ($3.79M) a year earlier.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$0$174K(100%) | Net income²($1.99M)($3.79M)47.4% | Diluted EPS³($0.08)($0.21)61.9% |
¹ Reported as “Revenue”. ² Reported as “Net loss attributable to Lexaria shareholders”. ³ Reported as “diluted loss per share”.
Business Highlights
- Completed the Phase 1b GLP-1‑H24‑4 clinical study and reported favorable safety and tolerability versus Rybelsus®.
- Advancing R&D across GLP-1, GIP, glucagon and CBD programs with multiple human and animal studies underway.
- Extended a materials transfer agreement with PharmaCO and received FDA clearance to proceed on an IND-based hypertension program.
- Revenue declined as the company shifted from prior B2B clients toward licensing and pharmaceutical development partnerships.
- Raised approximately $6.5M in two registered offerings to fund clinical trials and R&D into fiscal 2027.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.